Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the biology of anemia and its clinical impact on patients with cancer
- Discuss efficacy and safety data related to appropriate use of erythropoiesis-stimulating agents (ESAs) in patients with cancer
- Evaluate the possible risks and benefits of ESAs in the management of anemia in the oncology setting
- Discuss recent updates from regulatory agencies and changes to practice guidelines regarding the clinical utility of ESAs
Topics covered include:
- Clinical Controversies in the Treatment of Anemia: Appropriate Use of ESAs in a Time of Change